forked from oncokb/oncokb-public
-
Notifications
You must be signed in to change notification settings - Fork 0
Commit
This commit does not belong to any branch on this repository, and may belong to a fork outside of the repository.
- Loading branch information
Showing
6 changed files
with
53 additions
and
27 deletions.
There are no files selected for viewing
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
20 changes: 13 additions & 7 deletions
20
...es/newsPage/markdown/NewsContent022025.md → ...es/newsPage/markdown/NewsContent022525.md
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
Original file line number | Diff line number | Diff line change |
---|---|---|
@@ -1,20 +1,26 @@ | ||
- Updated Therapeutic Implications - Promotion of tumor type-specific level of evidence for an alteration | ||
|
||
| Gene | Mutation | Cancer Type | Level-associated Drug(s) in OncoKB™ | Previous Level | Updated Level | Evidence | | ||
| :---- | :------------------ | :------------------------- | :-------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------- | :------------ | :--------------------------------------------------------------------------------------------------------------------------- | | ||
| FGFR1 | Fusions | Pancreatic Cancer | _Drug(s) promoted in OncoKB™:_ Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | | ||
| FGFR2 | Fusions | Pancreatic Cancer | _Drug(s) promoted in OncoKB™:_ Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | | ||
| FGFR2 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_ Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Fexagratinib, Lirafugratinib (Level 4\) | 4 | 2 | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | | ||
| FGFR3 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_ Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | | ||
| Gene | Mutation | Cancer Type | Level-associated Drug(s) in OncoKB™ | Previous Level | Updated Level | Evidence | | ||
| :---- | :------------------ | :------------------------- | :---------------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------- | :------------ | :--------------------------------------------------------------------------------------------------------------------------- | | ||
| FGFR1 | Fusions | Pancreatic Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | | ||
| FGFR2 | Fusions | Pancreatic Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | | ||
| FGFR2 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib, Lirafugratinib (Level 4\) | 4 | 2 | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | | ||
| FGFR3 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) | | ||
|
||
- Updated Therapeutic Implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence) | ||
|
||
| Level | Gene | Mutation | Cancer Type | Level-Associated Drug(s) in OncoKB™ | Drug(s) Added to OncoKBTM | Evidence | | ||
| :---- | :--- | :------- | :---------------- | :---------------------------------- | :---------------------------------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | | ||
| 1 | BRAF | V600E | Colorectal Cancer | Encorafenib \+ Cetuximab (Level 1\) | Encorafenib \+ Cetuximab \+ FOLFOX Regimen (Level 1\) | [FDA approval of encorafenib with cetuximab and mFOLFOX6](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-encorafenib-cetuximab-and-mfolfox6-metastatic-colorectal-cancer-braf); PMID: [39863775](https://pubmed.ncbi.nlm.nih.gov/39863775/) | | ||
|
||
- Addition of 4 new genes: | ||
#### | ||
|
||
- Addition of 8 new genes: | ||
- ALOX5 | ||
- APEX1 | ||
- CBLB | ||
- DHX15 | ||
- POLH | ||
- RPS6KB1 | ||
- TACSTD2 | ||
- WEE1 |